BUB1B and ovarian serous carcinoma: BUB1B was also involved in the molecular regulation of EMT and associated with poor early survival of ovarian serous carcinoma at stages I+II 33, indicating BUB1B as a key biomarker for early clinical diagnosis and prognosis evaluation of patients.